C
Chalice Brands Ltd.
CNSX:CHAL
Chalice Brands Ltd.
CNSX:CHAL
Price:
0.225
CAD
Market Closed
Market Cap:
CA$19m
Relative Value
There is not enough data to reliably calculate the relative value of CHAL.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CHAL
Relative Value
Base Case
Not Available
Multiples Across Competitors
CHAL Competitors Multiples
Chalice Brands Ltd. Competitors
Chalice Brands Ltd. Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
C
|
Chalice Brands Ltd.
CNSX:CHAL
|
19m CAD | 0.4 | -1.3 | -14.5 | -6.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD | 17.7 | 57 | 38.2 | 41 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD | 6 | 21.1 | 14.7 | 18 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282.5B CHF | 4.6 | 30.1 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226B CHF | 5.2 | 20.2 | 12.7 | 16.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.5B GBP | 5.1 | 31.4 | 15 | 21.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.3 | 13 | 9.1 | 10.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD | 2.4 | 19.7 | 7.4 | 9.8 | |
| FR |
|
Sanofi SA
PAR:SAN
|
98.3B EUR | 1.7 | 8.2 | 7.6 | 7.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
